search
Back to results

Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children

Primary Purpose

Zinc Deficiency, Diarrhea, Malaria

Status
Completed
Phase
Not Applicable
Locations
Burkina Faso
Study Type
Interventional
Intervention
Daily preventive Zn; placebo treatment
Therapeutic Zn; daily placebo
Intermittent Zn; placebo treatment
Surveillance control group
Sponsored by
University of California, Davis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Zinc Deficiency focused on measuring zinc supplementation, diarrhea management, zinc deficiency, malaria

Eligibility Criteria

6 Months - 27 Months (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 6-27 months of age
  • Plan to remain in study area for 1 year

Exclusion Criteria:

  • Evidence of congenital abnormalities and chronic infection
  • Severe anemia and severe acute malnutrition
  • Consumption of micronutrient supplementation including zinc

Sites / Locations

  • Institut de Recherche en Science de la Sante

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Active Comparator

No Intervention

Arm Label

Daily preventive Zn; placebo treatment

Therapeutic Zn; daily placebo

Intermittent Zn; placebo treatment

Surveillance control group

Non-intervention

Arm Description

7 mg zinc per day for 12 months and placebo supplement during diarrhea episode

20 mg of zinc for 10 days during episodes of diarrhea and daily placebo supplement

10 mg zinc for 10 days every 3 months, daily placebo during 80 days of 3 months period and placebo during diarrhea episode

Surveillance control group will be randomly assigned to intervention groups every 3 months

Standard care provided by health system

Outcomes

Primary Outcome Measures

Change in length and length-for-age Z-score
Change in weight and weight-for-age
Incidence of diarrhea and laboratory-confirmed malaria
Change in plasma zinc concentration

Secondary Outcome Measures

Incidence of stunting, underweight, and wasting
Change in hemoglobin and iron status

Full Information

First Posted
July 21, 2009
Last Updated
July 11, 2018
Sponsor
University of California, Davis
Collaborators
Université Polytechnique de Bobo-Dioulasso, Helen Keller International, Thrasher Research Fund, Canadian International Development Agency
search

1. Study Identification

Unique Protocol Identification Number
NCT00944359
Brief Title
Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children
Official Title
Community-based Intervention Trial to Compare the Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children in Burkina Faso
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
February 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, Davis
Collaborators
Université Polytechnique de Bobo-Dioulasso, Helen Keller International, Thrasher Research Fund, Canadian International Development Agency

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Zinc supplementation can either be provided in a lower daily dose to prevent zinc deficiency or in a higher dose for 10-14 days as part of the treatment of diarrhea. It is important to determine how best to integrate programs designed either to prevent zinc deficiency or to treat diarrhea. The overall objective of this project is to determine the most effective approach to prevent zinc deficiency and treat diarrhea, such that a single approach could provide the maximal beneficial impact on the health and nutritional status of young children and greatest simplicity of implementation.
Detailed Description
This is a single-center cluster- and household-randomized, partially masked, community-based efficacy trial of zinc supplementation. The study sample consists of 5 study groups in one region, with 34 clusters randomly assigned to 3 types of intervention communities. Communities will be randomly assigned to 1) early intervention communities, 2) later intervention communities, 3) non-intervention communities. Within each intervention cluster, children will be randomly assigned to the intervention group at the household level. Children aged 6-27 months at enrollment will be eligible. The study duration is 12 months. The investigators will assess the relative impact of daily preventive zinc supplementation (7 mg zinc/d for one year), intermittent preventive supplementation (10 mg zinc/d for 10 days every three months for one year), and zinc treatment during episodes of diarrhea (20 mg zinc/d for 10 days beginning with each episode of diarrhea during one year). Outcomes that will be assessed include the incidence and duration of all episodes of diarrhea, the incidence of malaria, physical growth, and (in a sub-group) biochemical indicators of zinc, iron and vitamin A status.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Zinc Deficiency, Diarrhea, Malaria
Keywords
zinc supplementation, diarrhea management, zinc deficiency, malaria

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
7680 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Daily preventive Zn; placebo treatment
Arm Type
Experimental
Arm Description
7 mg zinc per day for 12 months and placebo supplement during diarrhea episode
Arm Title
Therapeutic Zn; daily placebo
Arm Type
Experimental
Arm Description
20 mg of zinc for 10 days during episodes of diarrhea and daily placebo supplement
Arm Title
Intermittent Zn; placebo treatment
Arm Type
Experimental
Arm Description
10 mg zinc for 10 days every 3 months, daily placebo during 80 days of 3 months period and placebo during diarrhea episode
Arm Title
Surveillance control group
Arm Type
Active Comparator
Arm Description
Surveillance control group will be randomly assigned to intervention groups every 3 months
Arm Title
Non-intervention
Arm Type
No Intervention
Arm Description
Standard care provided by health system
Intervention Type
Dietary Supplement
Intervention Name(s)
Daily preventive Zn; placebo treatment
Other Intervention Name(s)
Nutriset preventive zinc and therapeutic placebo supplement
Intervention Description
7 mg zinc / day and placebo supplement during diarrhea episodes
Intervention Type
Dietary Supplement
Intervention Name(s)
Therapeutic Zn; daily placebo
Other Intervention Name(s)
Nutriset ZinCfant
Intervention Description
20 mg zinc / day for 10 days during diarrhea episodes and daily placebo supplement
Intervention Type
Dietary Supplement
Intervention Name(s)
Intermittent Zn; placebo treatment
Other Intervention Name(s)
Nutriset zinc supplement
Intervention Description
10 mg zinc for 10 days every 3 months, placebo supplements daily for all other days during 12 months; placebo supplements during diarrhea episodes
Intervention Type
Other
Intervention Name(s)
Surveillance control group
Intervention Description
Active weekly morbidity surveillance for 3 months. New surveillance control group will be randomly assigned to intervention groups every 3 months
Primary Outcome Measure Information:
Title
Change in length and length-for-age Z-score
Time Frame
12 months
Title
Change in weight and weight-for-age
Time Frame
12 months
Title
Incidence of diarrhea and laboratory-confirmed malaria
Time Frame
12 months
Title
Change in plasma zinc concentration
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Incidence of stunting, underweight, and wasting
Time Frame
12 months
Title
Change in hemoglobin and iron status
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
27 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 6-27 months of age Plan to remain in study area for 1 year Exclusion Criteria: Evidence of congenital abnormalities and chronic infection Severe anemia and severe acute malnutrition Consumption of micronutrient supplementation including zinc
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kenneth H Brown, MD
Organizational Affiliation
University of California, Davis
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institut de Recherche en Science de la Sante
City
Bobo-Dioulasso
Country
Burkina Faso

12. IPD Sharing Statement

Citations:
PubMed Identifier
27489011
Citation
Becquey E, Ouedraogo CT, Hess SY, Rouamba N, Prince L, Ouedraogo JB, Vosti SA, Brown KH. Comparison of Preventive and Therapeutic Zinc Supplementation in Young Children in Burkina Faso: A Cluster-Randomized, Community-Based Trial. J Nutr. 2016 Oct;146(10):2058-2066. doi: 10.3945/jn.116.230128. Epub 2016 Aug 3.
Results Reference
result
PubMed Identifier
28771493
Citation
Hess SY, Peerson JM, Becquey E, Abbeddou S, Ouedraogo CT, Some JW, Yakes Jimenez E, Ouedraogo JB, Vosti SA, Rouamba N, Brown KH. Differing growth responses to nutritional supplements in neighboring health districts of Burkina Faso are likely due to benefits of small-quantity lipid-based nutrient supplements (LNS). PLoS One. 2017 Aug 3;12(8):e0181770. doi: 10.1371/journal.pone.0181770. eCollection 2017.
Results Reference
result

Learn more about this trial

Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children

We'll reach out to this number within 24 hrs